GDF15: A Literature Course on What It Is and What the Studies Report

This course walks through the published literature on GDF15 in six modules. It describes what researchers measured, in which models, and what they reported \u2014 not what anyone should do. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Every claim below is tied to a cited paper in the same sentence, and each module closes with the limits of that evidence.

Module 1 \u2014 What GDF15 Is and How It Has Been Studied

Definition and class

GDF15 stands for growth differentiation factor 15. Reviews have described it as a distant, structurally divergent member of the transforming growth factor-\u03b2 (TGF-\u03b2) superfamily that circulates in blood and behaves like a hormone rather than a local growth factor (PMID 32310257). A 2021 review in Nature Reviews Endocrinology framed GDF15 as an emerging node in obesity and cardiometabolic biology, positioning it alongside other stress-responsive circulating factors (PMID 34381196).

Other names and molecular forms

The same protein appears in older literature under several names, including MIC-1, NAG-1, PLAB and placental bone morphogenetic protein, which reflects the fact that separate research groups discovered it in macrophage, gastrointestinal and placental contexts (PMID 34836750). Reviews describe GDF15 as being made first as a precursor protein that is processed and secreted, with the mature signalling species circulating as a disulfide-linked dimer (PMID 32310257).

Where it comes from and how it has been studied

Published work reports that GDF15 is expressed at low levels in most tissues under basal conditions and rises sharply with cellular stress, tissue injury, inflammation, mitochondrial dysfunction and pregnancy, which is why some authors group it with FGF21 as a \u201cmitokine\u201d or stress signal (PMID 34526227). The research base has three main strands: observational studies measuring circulating GDF15 as a biomarker, animal experiments administering or deleting the protein, and human genetics. A 2024 paper in Nature Metabolism identified and characterised human GDF15 knockouts \u2014 individuals with genetically determined loss of the protein \u2014 which showed that complete absence of GDF15 could be observed and studied in living adults (PMID 39327531).

Limits of the evidence in Module 1

Much of the descriptive literature is review-level rather than primary experiment, and a 2025 commentary in Trends in Endocrinology & Metabolism argued explicitly that GDF15 remains a \u201cmystery hormone\u201d whose full physiological role is unresolved (PMID 39472228). Naming conventions across decades make older literature hard to compare, and assay differences complicate cross-study comparison of circulating concentrations.

Module 2 \u2014 Mechanism as Described in the Literature

The GFRAL receptor and the hindbrain

The central mechanistic finding in the modern GDF15 literature is receptor localisation: reviews describe GDF15 binding to GFRAL, a receptor expressed in a restricted region of the hindbrain (the area postrema and nucleus tractus solitarius), where it recruits the co-receptor RET to transmit signal (PMID 32310257). Because that brainstem region sits outside the tight blood\u2013brain barrier, authors have described GDF15 as a route by which peripheral somatic distress is conveyed directly to the brain (PMID 32310257).

Stress signalling upstream

Upstream, reviews report that transcription of GDF15 is induced by integrated stress response pathways, mitochondrial dysfunction, oxidative stress and inflammatory stimuli, and that circulating levels track the intensity of that stress rather than a single tissue source (PMID 34526227). A 2022 review in Cytokine & Growth Factor Reviews described this stress-induction pattern as the common thread linking GDF15 elevation in obesity, cancer and cachexia (PMID 34836750).

Downstream effects described in models

Downstream of GFRAL, the literature reports suppression of food intake and reduction of body weight in animal models, alongside aversive behavioural responses (PMID 31928886). A separate line of work in Cell reported that GDF15 acted centrally as a mediator of tissue tolerance during inflammation, influencing sympathetic outflow and metabolic substrate handling rather than acting as a direct anti-pathogen effector (PMID 31402172).

Limits of the evidence in Module 2

Mechanistic work is dominated by rodent models, and reviewers have noted that GFRAL-independent actions, tissue-level effects and the physiological purpose of chronic elevation are still debated (PMID 39472228). Receptor-level detail does not establish that modulating the pathway produces a clinical benefit in humans.

Module 3 \u2014 Reported Outcomes by Study

The table summarises what the cited papers examined and reported. No dose figures are given here because the verified literature summarised on this page does not present administration regimens that can be quoted accurately.

Metabolic and obesity-related reports

A 2021 review summarised preclinical and translational work positioning GDF15 as a regulator of energy balance and a candidate pathway for obesity and cardiometabolic disease, while noting that therapeutic application remained in development rather than established practice (PMID 34381196). Related work has described GDF15 and FGF21 as parallel stress-induced signals that rise in obesity and in states of obesity resistance, complicating simple interpretations of high circulating levels (PMID 34526227).

Cancer and cachexia reports

In oncology, a 2024 Cancer Cell review traced GDF15 research from laboratory characterisation toward clinical translation, describing both agonist and antagonist strategies under study (PMID 39454578). A 2025 review focused specifically on cancer cachexia reported that elevated GDF15 tracked with appetite loss and wasting, and that blocking the pathway had become an active therapeutic target rather than a settled treatment (PMID 40640073).

Limits of the evidence in Module 3

Most outcome data are associative (biomarker studies) or preclinical (rodent experiments). Association between high GDF15 and poor outcomes does not establish causation, and reviewers have emphasised that whether elevation is harmful, protective or simply a marker of underlying stress remains contested (PMID 39472228). None of the cited papers establish an approved therapeutic use.

Module 4 \u2014 GDF15 Side Effects: What Studies Report

Nausea, emesis and aversion in animal models

The most consistently reported adverse effect is aversive: a 2020 study in Cell Metabolism reported that GDF15-induced anorexia occurred through nausea and emesis rather than through a neutral reduction in appetite, with emetic responses observed in species able to vomit (PMID 31928886). Reviews have repeated this point, noting that because GDF15 signals through the area postrema \u2014 a region classically associated with vomiting \u2014 nausea has been treated as a mechanistically expected consequence of pathway activation rather than an incidental finding (PMID 32310257). A 2021 review on therapeutic applications discussed this aversion as a central obstacle for developing GDF15-based approaches to obesity (PMID 34381196).

Weight loss, wasting and appetite suppression as harms

In the cancer setting, the same biology has been described as harmful: reviews report that elevated GDF15 in patients with cancer associated with anorexia, involuntary weight loss and cachexia, which is why antagonism rather than agonism has been pursued in that context (PMID 40640073). A 2022 review described the same protein as pathophysiologically implicated across obesity, cancer and cachexia, underscoring that the direction of \u201cbenefit\u201d depends entirely on the clinical setting (PMID 34836750).

Pregnancy-related and other reported associations

Reviews also note that GDF15 rises substantially in pregnancy and has been linked in the literature to nausea and vomiting of pregnancy, connecting the hormone's physiological elevation to symptomatic burden (PMID 39472228). Separately, the 2024 human knockout paper examined what happens when the protein is absent rather than elevated, which is the complementary safety question (PMID 39327531).

Limits of the evidence in Module 4

Adverse-event information here comes largely from animal experiments and observational human data, not from controlled safety trials of administered GDF15 in healthy people. There is no systematic human adverse-event table in the cited literature, no long-term safety follow-up of exogenous administration, and no characterisation of interaction risks.

Module 5 \u2014 Pharmacokinetics Where Data Exist

Formal human pharmacokinetic parameters for administered GDF15 \u2014 half-life, clearance, bioavailability by route \u2014 are not presented in the verified literature summarised here, and no numeric values are quoted for that reason. What the literature does describe is the behaviour of endogenous GDF15.

• Circulating GDF15 is measurable in plasma and serum by immunoassay, and reviews report that levels rise with cellular stress, inflammation and disease burden (PMID 34526227).
• A 2022 review reported that circulating concentrations increase with chronological age and associate with age-related outcomes, making baseline level strongly dependent on population (PMID 35051643).
• Reviews of therapeutic development describe engineering approaches intended to extend exposure of GDF15-based molecules, indicating that the native protein's circulating persistence was considered a development constraint (PMID 34381196).
• Because signalling occurs at a circumventricular hindbrain site, reviews note that the relevant exposure question is access to the area postrema rather than general brain penetration (PMID 32310257).

Limits of the evidence in Module 5

Without published dose\u2013exposure data in humans, no statements about duration of action, accumulation or route comparison can be made from these sources. Assay-to-assay variability also means absolute concentrations reported in different cohorts are not directly interchangeable.

Module 6 \u2014 Regulatory Status, Stated Factually

Approved products

There is no approved GDF15 drug product for general therapeutic use. The cited reviews describe GDF15-directed agents \u2014 both pathway agonists explored for metabolic disease and pathway antagonists explored for cachexia \u2014 as being in research and clinical development rather than in approved practice (PMID 39454578, PMID 40640073).

Research-use-only materials

Recombinant GDF15 protein and anti-GDF15 reagents are distributed as research-use-only (RUO) laboratory materials. RUO labelling means a material is intended for laboratory investigation and is not manufactured, tested or labelled as a drug for administration to humans or animals.

Compounding

In the United States, compounding pharmacies operate under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which limit compounding to substances that are the subject of an applicable monograph, are components of an approved drug, or appear on the relevant FDA bulk drug substances lists. GDF15 is a protein that does not correspond to an approved drug product, and no approved GDF15 product exists from which a compounded preparation could be derived. Biological products are also treated differently from small molecules under the Public Health Service Act. This is general regulatory information, not legal advice.

Limits of the evidence in Module 6

Regulatory status changes over time and differs by country; the literature cited here addresses science rather than law, and development-stage descriptions in reviews reflect the moment those reviews were written.

What the Studies Did Not Test

Reading the cited body of work together, several questions remain outside its scope:

1. Administration to healthy people. None of the cited papers reported controlled administration of GDF15 to healthy human volunteers for performance, body composition or longevity endpoints.
2. Dose and schedule. No regimen \u2014 amount, frequency or duration \u2014 can be quoted from these sources, and none is offered here.
3. Long-term safety. The reviews discuss aversive effects and disease associations, but no long-term human safety dataset for exogenous GDF15 is described (PMID 34381196).
4. Causality of biomarker elevation. Whether high GDF15 causes poor outcomes or reflects them was explicitly left open by reviewers (PMID 39472228).
5. Combination use. No interaction, stacking or co-administration studies with other compounds appear in the cited set.
6. Subgroup effects. Sex, age, renal function and comorbidity effects on GDF15 signalling were not systematically resolved, though age dependence of circulating levels was reported (PMID 35051643).

The literature on GDF15 is unusually active and unusually unsettled: the same hormone is a drug target for weight reduction in one field and a drug target for blockade in another. Readers evaluating claims about GDF15 can reasonably ask which setting, which species and which direction of manipulation a given statement refers to. This page is educational only and is not medical advice; a licensed physician is the appropriate source for individual guidance.

References

• GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease (Nature Reviews Endocrinology, 2021)
• GDF15 research from bench to bedside (Cancer Cell, 2024)
• GDF15 is still a mystery hormone (Trends in Endocrinology and Metabolism, 2025)
• Stress-induced FGF21 and GDF15 in obesity and obesity resistance (Trends in Endocrinology and Metabolism, 2021)
• Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia (Cytokine & Growth Factor Reviews, 2022)
• Identification and characterization of human GDF15 knockouts (Nature Metabolism, 2024)
• GDF15, an emerging key player in human aging (Ageing Research Reviews, 2022)
• GDF15: A Hormone Conveying Somatic Distress to the Brain (Endocrine Reviews, 2020)
• GDF15 Induces Anorexia through Nausea and Emesis (Cell Metabolism, 2020)
• GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance (Cell, 2019)
• GDF15 and LCN2 for early detection and prognosis of pancreatic cancer (Translational Oncology, 2024)
• GDF15: from biomarker to target in cancer cachexia (Trends in Cancer, 2025)